These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6765207)

  • 21. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M
    Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Calmette-Guerin bacillus disseminated infection after intravesical instillation].
    Borré S; Brustia D; Rosa F; Brondolo R; Rizzo G; Garavelli PL
    Recenti Prog Med; 2002 Apr; 93(4):247-8. PubMed ID: 11989131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current advances in cancer immunotherapy (author's transl)].
    Belpomme D; Marty M; Gisselbrecht C; Mignot L; Pujade-Lauraine E
    Sem Hop; 1981 Oct 8-15; 57(37-38):1547-56. PubMed ID: 6270825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developments in immunotherapy.
    Krakowka S
    Mod Vet Pract; 1981 Jun; 62(6):447-51. PubMed ID: 6166843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. New prospects for an old warhorse.
    O'Donnell MA; DeWolf WC
    Surg Oncol Clin N Am; 1995 Apr; 4(2):189-202. PubMed ID: 7796280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Systemic BCG reactions after intravesical BCG therapy. A report of four cases].
    Sfaxi M; Langar H; Ouni A; Riahi Y; El Aidli S; Daghfous R; Ben Abdeladhim A; Chébil M
    Therapie; 2008; 63(1):43-7. PubMed ID: 18387275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer.
    Dovedi SJ; Kirby JA; Atkins H; Davies BR; Kelly JD
    J Urol; 2005 Jul; 174(1):332-7; discussion 337. PubMed ID: 15947685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bladder contracture: review for intravesical bacillus Calmette-Guerin complication.
    Hameed A; Sezian N; Thwaini A
    Can J Urol; 2007 Dec; 14(6):3745-9. PubMed ID: 18163926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement.
    Brandau S; Suttmann H
    Biomed Pharmacother; 2007 Jul; 61(6):299-305. PubMed ID: 17604943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mathematical model of BCG immunotherapy in superficial bladder cancer.
    Bunimovich-Mendrazitsky S; Shochat E; Stone L
    Bull Math Biol; 2007 Aug; 69(6):1847-70. PubMed ID: 17457655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V; Pode D; Pikarsky E; Mandelboim O
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
    Lee CF; Chang SY; Hsieh DS; Yu DS
    J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunotherapy of cancer].
    Andersen MH; Schmidt H; Gehl J; von der Maase H; Straten P
    Ugeskr Laeger; 2002 Jun; 164(23):3008-16. PubMed ID: 12082849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.
    Lamm DL
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S86-90. PubMed ID: 11010830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Poly-immunotherapy anti-cancer in man].
    de Sá CA; Ismael C; Miguez LA; Pereira Mde L; Leão Sde S; Fernandes ZZ
    Rev Hosp Clin Fac Med Sao Paulo; 1978 Jun; 33(3):167-73. PubMed ID: 684322
    [No Abstract]   [Full Text] [Related]  

  • 38. [Inhibition of neoplasms by stimulation of immunity. Experimental aspects (with review of the questions discussed)].
    Lemonde P
    Union Med Can; 1974 Oct; 103(10):1716-28. PubMed ID: 4378396
    [No Abstract]   [Full Text] [Related]  

  • 39. [Non-specific vaccinotherapy].
    Brottier E; Guillaume D; Gin H; Aubertin J
    Rev Prat; 1983 Oct; 33(45):2427-39. PubMed ID: 6648280
    [No Abstract]   [Full Text] [Related]  

  • 40. Personal experience with Corynebacterium parvum in human cancers.
    Israël L; Edelstein R
    World J Surg; 1977 Sep; 1(5):585-95. PubMed ID: 602233
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.